LYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.63 USD | -11.81% |
|
-10.44% | -11.64% |
| 30/04 | Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 19/04 | Lyra Therapeutics, Inc. Announces Board Changes | CI |
Evolution of the average Target Price on Lyra Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
7f19950625652be951ffd.dHKjUeVr7VDsxyev6CXrEKYtw1hEW7tEqnw1oNAWhBs.Kxr2EoYenAaA6kn2hR2xZM19gTEjAfUR-SpC2pxH6kouGswoiCiVPr2NZg~04ff6cc32e8f4bcd942a3ef6c22594cd
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.63
USD
Average target price
11.6
USD
Spread / Average Target
+150.54%
High Price Target
15
USD
Spread / Highest target
+223.97%
Low Price Target
10
USD
Spread / Lowest Target
+115.98%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lyra Therapeutics, Inc.
| BTIG | |
| BofA Securities | |
| HC Wainwright | |
| Cantor Fitzgerald |
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
- Stock Market
- Equities
- LYRA Stock
- Consensus Lyra Therapeutics, Inc.
